

# Hiroyuki Shimada

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12331/publications.pdf>

Version: 2024-02-01

153  
papers

11,413  
citations

50276

46  
h-index

29157

104  
g-index

154  
all docs

154  
docs citations

154  
times ranked

8361  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid. <i>New England Journal of Medicine</i> , 1999, 341, 1165-1173.	27.0	1,722
2	The International Neuroblastoma Pathology Classification (the Shimada system). <i>Cancer</i> , 1999, 86, 364-372.	4.1	940
3	Histopathologic Prognostic Factors in Neuroblastic Tumors: Definition of Subtypes of Ganglioneuroblastoma and an Age-Linked Classification of Neuroblastomas. <i>Journal of the National Cancer Institute</i> , 1984, 73, 405-416.	6.3	796
4	Terminology and morphologic criteria of neuroblastic tumors. <i>Cancer</i> , 1999, 86, 349-363.	4.1	583
5	Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. <i>New England Journal of Medicine</i> , 2005, 353, 2243-2253.	27.0	495
6	Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	298
7	International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors. <i>Cancer</i> , 2001, 92, 2451-2461.	4.1	273
8	Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. <i>New England Journal of Medicine</i> , 2010, 363, 1313-1323.	27.0	253
9	Revision of the International Neuroblastoma Pathology Classification. <i>Cancer</i> , 2003, 98, 2274-2281.	4.1	249
10	Favorable Biology and Outcome of Stage IV-S Neuroblastoma With Supportive Care or Minimal Therapy: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 477-477.	1.6	243
11	Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3525-3532.	1.6	236
12	Biologic Variables in the Outcome of Stages I and II Neuroblastoma Treated With Surgery as Primary Therapy: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 18-18.	1.6	218
13	Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 1260-1268.	1.6	212
14	Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1193-1203.	6.3	212
15	Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641. <i>Journal of Clinical Oncology</i> , 2012, 30, 1842-1848.	1.6	174
16	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3229-3241.	1.6	174
17	Identification of Subsets of Neuroblastomas by Combined Histopathologic and N-myc Analysis. <i>Journal of the National Cancer Institute</i> , 1995, 87, 1470-1476.	6.3	154
18	Double Staining with Brilliant Blue G and Double Peeling for Epiretinal Membranes. <i>Ophthalmology</i> , 2009, 116, 1370-1376.	5.2	151

#	ARTICLE	IF	CITATIONS
19	Current Treatment Protocols Have Eliminated the Prognostic Advantage of Type 1 Fusions in Ewing Sarcoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 1989-1994.	1.6	138
20	Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6474-6480.	1.6	133
21	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. <i>Cancer</i> , 2001, 92, 2699-2708.	4.1	132
22	Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. <i>Cancer Research</i> , 2017, 77, 5142-5157.	0.9	130
23	25-Gauge Scleral Tunnel Transconjunctival Vitrectomy. <i>American Journal of Ophthalmology</i> , 2006, 142, 871-873.	3.3	125
24	Incidence of Endophthalmitis after 20- and 25-Gauge Vitrectomy. <i>Ophthalmology</i> , 2008, 115, 2215-2220.	5.2	122
25	Critical Role of STAT3 in IL-6-Mediated Drug Resistance in Human Neuroblastoma. <i>Cancer Research</i> , 2013, 73, 3852-3864.	0.9	109
26	Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: Histopathologic features-A report from the children's cancer group. <i>Medical and Pediatric Oncology</i> , 2001, 36, 623-629.	1.0	105
27	Mouse Mesenchymal Stem Cells Expressing PAX-FKHR Form Alveolar Rhabdomyosarcomas by Cooperating with Secondary Mutations. <i>Cancer Research</i> , 2008, 68, 6587-6597.	0.9	102
28	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Cancer</i> , 2017, 123, 4224-4235.	4.1	97
29	Human and mouse tissue-engineered small intestine both demonstrate digestive and absorptive function. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, G664-G677.	3.4	88
30	Malignant rhabdoid tumor. A study with two established cell lines. <i>Cancer</i> , 1993, 71, 2862-2872.	4.1	85
31	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. <i>Nature Communications</i> , 2021, 12, 511.	12.8	85
32	Expanded Indications for 25-Gauge Transconjunctival Vitrectomy. <i>Japanese Journal of Ophthalmology</i> , 2005, 49, 397-401.	1.9	82
33	Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. <i>Pediatric Blood and Cancer</i> , 2009, 53, 563-569.	1.5	79
34	Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. <i>Cancer</i> , 2017, 123, 1095-1105.	4.1	75
35	Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 1885-1890.	1.9	71
36	JC virus detection by in situ hybridization in brain tissue from elderly patients. <i>Annals of Neurology</i> , 1991, 29, 428-432.	5.3	70

#	ARTICLE	IF	CITATIONS
37	Phase I Study of Vincristine, Irinotecan, and <sup>131</sup> I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2679-2686.	7.0	69
38	Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. <i>Cancer</i> , 2013, 119, 3718-3726.	4.1	67
39	Dose Escalation Study of No-Carrier-Added <sup>131</sup> I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1155-1163.	5.0	64
40	International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. <i>European Journal of Cancer</i> , 2006, 42, 1113-1119.	2.8	63
41	Phase I Study of Vorinostat as a Radiation Sensitizer with <sup>131</sup> I-Metaiodobenzylguanidine ( <sup>131</sup> I-MIBC) for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 2715-2721.	7.0	62
42	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , 2019, 37, 3243-3255.	1.6	61
43	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. <i>European Journal of Cancer</i> , 2016, 65, 1-10.	2.8	56
44	Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. <i>Japanese Journal of Ophthalmology</i> , 2008, 52, 282-288.	1.9	55
45	Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells. <i>Clinical Cancer Research</i> , 2019, 25, 4761-4774.	7.0	53
46	Concentration Gradient of Vascular Endothelial Growth Factor in the Vitreous of Eyes with Diabetic Macular Edema. , 2009, 50, 2953.		51
47	Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6097-6102.	7.1	50
48	Morphologic features of neuroblastoma (Schwannian stroma-poor tumors) in clinically favorable and unfavorable groups. <i>Cancer</i> , 2002, 94, 1574-1583.	4.1	49
49	Large cell neuroblastoma. <i>Cancer</i> , 2004, 100, 390-397.	4.1	49
50	Histopathology defines prognostic subsets of ganglioneuroblastoma, nodular. <i>Cancer</i> , 2000, 89, 1150-1161.	4.1	47
51	Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1332941.	12.2	47
52	Matrix Metalloproteinases and Their Inhibitors in Tumor Progression. <i>Annals of the New York Academy of Sciences</i> , 1994, 732, 222-232.	3.8	45
53	Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , 2019, 37, 115-124.	1.6	45
54	Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. <i>Oncotarget</i> , 2017, 8, 91516-91529.	1.8	45

#	ARTICLE	IF	CITATIONS
55	One hundred neuroblastomas detected through a mass screening system in Japan. <i>Cancer</i> , 1994, 74, 3223-3226.	4.1	39
56	Enlarged and prominent nucleoli may be indicative of MYCN amplification. <i>Cancer</i> , 2005, 103, 174-180.	4.1	38
57	Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. <i>Clinical Cancer Research</i> , 2017, 23, 5374-5383.	7.0	38
58	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3514.	1.6	38
59	Tumoral invasion in the central nervous system. <i>Journal of Neuro-Oncology</i> , 1993, 18, 111-121.	2.9	36
60	Pathology of peripheral neuroblastic tumors: Significance of prominent nucleoli in undifferentiated/poorly differentiated neuroblastoma. <i>Pathology and Oncology Research</i> , 2007, 13, 269-275.	1.9	36
61	Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2006, 12, 5693-5697.	7.0	35
62	Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group. <i>Pediatric and Developmental Pathology</i> , 2014, 17, 441-449.	1.0	35
63	Implantable chemotherapy-loaded silk protein materials for neuroblastoma treatment. <i>International Journal of Cancer</i> , 2017, 140, 726-735.	5.1	35
64	Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter <sup>®</sup> system. <i>Molecular Oncology</i> , 2014, 8, 669-678.	4.6	32
65	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MK1 neuroblastomas: a report from the children's oncology group. <i>Oncotarget</i> , 2018, 9, 6416-6432.	1.8	31
66	Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy. <i>Ophthalmology</i> , 2016, 123, 1278-1286.	5.2	30
67	Screening for neuroblastoma in north america. Preliminary results of a pathology review from the quebec project. <i>Cancer</i> , 1995, 76, 2363-2371.	4.1	28
68	Combined Replenishment of miR-34a and let-7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models. <i>Small</i> , 2020, 16, e1906426.	10.0	27
69	Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. <i>Pediatric Blood and Cancer</i> , 2013, 60, 363-370.	1.5	25
70	Association of high microvessel density and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. <i>Oncotarget</i> , 2017, 8, 52193-52210.	1.8	24
71	Frequency, source, and prevention of cotton fibers in the anterior chamber during cataract surgery. <i>Journal of Cataract and Refractive Surgery</i> , 2008, 34, 1389-1392.	1.5	22
72	Reduced anterior chamber contamination by frequent surface irrigation with diluted iodine solutions during cataract surgery. <i>Acta Ophthalmologica</i> , 2017, 95, e373-e378.	1.1	22

#	ARTICLE	IF	CITATIONS
73	Utility of Phox2b immunohistochemical stain in neural crest tumours and non-neural crest tumours in paediatric patients. <i>Histopathology</i> , 2018, 72, 685-696.	2.9	22
74	Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. <i>Oncolmunology</i> , 2021, 10, 1838140.	4.6	22
75	IMAGE ANALYSIS FOR AUTOMATED ASSESSMENT OF GRADE OF NEUROBLASTIC DIFFERENTIATION. , 2007, , .		21
76	The clinical management and outcomes of cervical neuroblastic tumors. <i>Journal of Surgical Research</i> , 2016, 204, 109-113.	1.6	20
77	Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2653-2664.	4.1	20
78	Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. <i>Clinical Cancer Research</i> , 2019, 25, 6044-6051.	7.0	20
79	Surgical excision of neovascularization in retinal angiomatous proliferation. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2005, 243, 519-524.	1.9	18
80	REDUCTION OF VITREOUS CONTAMINATION RATE AFTER 25-GAUGE VITRECTOMY BY SURFACE IRRIGATION WITH 0.25% POVIDONE-IODINE. <i>Retina</i> , 2013, 33, 143-151.	1.7	18
81	Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression. <i>Journal of Pediatric Surgery</i> , 2019, 54, 1192-1197.	1.6	18
82	MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. <i>Cell Death and Disease</i> , 2020, 11, 368.	6.3	18
83	Pathology review of screening negative neuroblastomas. , 1998, 83, 575-581.		17
84	Computer-Aided Grading of Neuroblastic Differentiation: Multi-Resolution and Multi-Classifer Approach. , 2007, , .		17
85	EFFECT OF OPERATIVE FIELD IRRIGATION ON INTRAOPERATIVE BACTERIAL CONTAMINATION AND POSTOPERATIVE ENDOPHTHALMITIS RATES IN 25-GAUGE VITRECTOMY. <i>Retina</i> , 2010, 30, 1242-1249.	1.7	17
86	Intravitreal Injection of 1.25% Povidone Iodine Followed by Vitrectomy Using 0.025% Povidone Iodine Irrigation for Treating Endophthalmitis. <i>Translational Vision Science and Technology</i> , 2019, 8, 21.	2.2	15
87	Foveal avascular zone area analysis in juvenile-onset type 1 diabetes using optical coherence tomography angiography. <i>Japanese Journal of Ophthalmology</i> , 2020, 64, 271-277.	1.9	15
88	Histopathologic features of composite ganglioneuroblastoma. Immunohistochemical distinction of the stromal component is related to prognosis. <i>Cancer</i> , 1990, 65, 255-264.	4.1	14
89	Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project. <i>European Journal of Cancer</i> , 2012, 48, 1185-1191.	2.8	14
90	Prophylaxis for acute scleral buckle infection using 0.25% povidone-iodine ocular surface irrigation during surgery. <i>International Ophthalmology</i> , 2014, 34, 211-216.	1.4	13

#	ARTICLE	IF	CITATIONS
91	Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>European Journal of Cancer</i> , 2020, 133, 112-119.	2.8	13
92	Cataract Surgery by Intraoperative Surface Irrigation with 0.25% Povidone-Iodine. <i>Journal of Clinical Medicine</i> , 2021, 10, 3611.	2.4	13
93	Twenty-gauge Transconjunctival Vitrectomy. <i>Japanese Journal of Ophthalmology</i> , 2005, 49, 257-260.	1.9	12
94	Thermal Injury Caused by Chandelier Fiber Probe. <i>American Journal of Ophthalmology</i> , 2007, 143, 167-169.	3.3	12
95	Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups. <i>Biomolecules</i> , 2022, 12, 79.	4.0	12
96	Histologic and ultrastructural features in early and advanced phases of Zellweger spectrum disorder (infantile Refsum disease). <i>Ultrastructural Pathology</i> , 2018, 42, 220-227.	0.9	11
97	Rare MYC-amplified Neuroblastoma With Large Cell Histology. <i>Pediatric and Developmental Pathology</i> , 2018, 21, 461-466.	1.0	11
98	Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model. <i>Cancer Medicine</i> , 2020, 9, 2891-2903.	2.8	11
99	Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 650427.	4.8	11
100	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 4107-4118.	1.6	11
101	Depiction of the vitreous pocket by optical coherence tomography. <i>International Ophthalmology</i> , 2011, 31, 51-53.	1.4	10
102	Am80 synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality. <i>EMBO Molecular Medicine</i> , 2016, 8, 1340-1359.	6.9	10
103	Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26940.	1.5	10
104	Terminology and morphologic criteria of neuroblastic tumors. <i>Cancer</i> , 1999, 86, 349-363.	4.1	10
105	Stage 4S Neuroblastoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1075-1081.	3.7	10
106	In Situ Neuroblastoma: An Important Concept Related to the Natural History of Neural Crest Tumors. <i>Pediatric and Developmental Pathology</i> , 2005, 8, 305-306.	1.0	9
107	MYCN-Dependent Expression of Sulfatase-2 Regulates Neuroblastoma Cell Survival. <i>Cancer Research</i> , 2014, 74, 5999-6009.	0.9	9
108	Subgrouping of Unfavorable Histology Neuroblastomas With Immunohistochemistry Toward Precision Prognosis and Therapy Stratification. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	3.0	9

#	ARTICLE	IF	CITATIONS
109	Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification. <i>Journal of Pediatric Surgery</i> , 2021, 56, 1199-1202.	1.6	9
110	Neuroblastoma Pathology and Biology. <i>Pathology International</i> , 1992, 42, 229-241.	1.3	8
111	Early onset of Rhegmatogenous retinal detachment after LASIK with femtosecond laser. <i>Japanese Journal of Ophthalmology</i> , 2009, 53, 75-76.	1.9	7
112	Relationship of Area of Soft Drusen in Retina with Cerebral Amyloid- $\beta^2$ Accumulation and Blood Amyloid- $\beta^2$ Level in the Elderly. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 239-245.	2.6	7
113	Capsular bag irrigation using 0.025% povidone-iodine in balanced salt solution PLUS for the treatment of postoperative endophthalmitis. <i>International Ophthalmology</i> , 2018, 38, 1787-1790.	1.4	7
114	No increase in incidence of post-intravitreal injection endophthalmitis without topical antibiotics: a prospective study. <i>Japanese Journal of Ophthalmology</i> , 2019, 63, 396-401.	1.9	7
115	Adjuvant CD49d Blockade Eradicates Chemo-resistant ALL. <i>Blood</i> , 2010, 116, 869-869.	1.4	7
116	A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children's Oncology Group study. <i>Journal of Clinical Oncology</i> , 2015, 33, 10017-10017.	1.6	7
117	Safety Measures for Maintaining Low Endophthalmitis Rate after Intravitreal Anti-Vascular Endothelial Growth Factor Injection before and during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2022, 11, 876.	2.4	7
118	A Clinicopathological Study on the Cardiac Rupture Following Myocardial Infarction in the Aged. <i>International Heart Journal</i> , 1968, 9, 265-280.	0.6	6
119	Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma. <i>Genes and Immunity</i> , 2022, 23, 129-140.	4.1	6
120	Reducing bacterial contamination inside fluid catch bag in 25-gauge vitrectomy by use of 0.25% povidone-iodine ocular surface irrigation. <i>International Ophthalmology</i> , 2013, 33, 35-38.	1.4	5
121	Low-concentration povidone-iodine for the prevention of intraocular infections in ophthalmic surgery. <i>Current Opinion in Ophthalmology</i> , 2022, 33, 28-34.	2.9	5
122	Highly viscous fluid in macular holes. <i>International Ophthalmology</i> , 2010, 30, 319-321.	1.4	4
123	Cytologic and Ultrastructural Findings of Bronchoalveolar Lavage in Patients With Chronic Granulomatous Disease. <i>Pediatric and Developmental Pathology</i> , 2018, 21, 347-354.	1.0	4
124	Enhancing sustained-release local therapy: Single versus dual chemotherapy for the treatment of neuroblastoma. <i>Surgery</i> , 2020, 167, 969-977.	1.9	4
125	Three-dimensional depiction of the vitreous pocket using triamcinolone acetonide. <i>European Journal of Ophthalmology</i> , 2009, 19, 1102-5.	1.3	4
126	Bilateral Pachychoroid disease with type 3 Uveal effusion syndrome in one eye and central serous Chorioretinopathy in contralateral eye: a case report. <i>BMC Ophthalmology</i> , 2022, 22, 91.	1.4	4



#	ARTICLE	IF	CITATIONS
127	One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy. <i>Journal of Clinical Medicine</i> , 2022, 11, 2175.	2.4	4
128	Clear Visualization of Anterior Vitreous Incarceration into Cannulae during 25-Gauge Vitrectomy in Eyes with Asteroid Hyalosis. <i>European Journal of Ophthalmology</i> , 2012, 22, 293-295.	1.3	3
129	Re: Merani etÂal.: Aqueous chlorhexidine for intravitreal injection antiseptis ( Ophthalmology.) Tj ETQq1 1 0.784314 rgBT /Overlock 1	5.2	3
130	International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors. , 2001, 92, 2451.		3
131	Bimanual anterior vitrectomy using a 25-gauge high-speed cutter to manage vitreous loss during phacoemulsification. <i>International Ophthalmology</i> , 2009, 29, 253-255.	1.4	2
132	Capsular bag irrigation using 0.025% povidone-iodine in balanced salt solution PLUS for the treatment of postoperative endophthalmitis. <i>International Ophthalmology</i> , 2018, 38, 2267-2268.	1.4	2
133	Pioneer in Pediatric Pathology: William A (Bill) Newton Jr (1923â€“). <i>Pediatric and Developmental Pathology</i> , 2019, 22, 91-97.	1.0	2
134	Large cell neuroblastoma â€“ Phenotypical variant of MYC-driven neuroblastoma: Report of 2 cases with different molecular characteristics. <i>Human Pathology: Case Reports</i> , 2021, 24, 200493.	0.2	2
135	The International Neuroblastoma Pathology Classification (the Shimada system). , 1999, 86, 364.		2
136	Pathology of Peripheral Neuroblastic Tumors. <i>Clinical Pediatric Hematology-Oncology</i> , 2020, 27, 73-86.	0.2	2
137	Transient increase in macular edema following vitrectomy for retinal branch vein occlusion. <i>International Ophthalmology</i> , 2009, 29, 95-98.	1.4	1
138	Replicating and identifying large cell neuroblastoma using high-dose intra-tumoral chemotherapy and automated digital analysis. <i>Journal of Pediatric Surgery</i> , 2019, 54, 2595-2599.	1.6	1
139	Age Inherently Links to Histology to Define Histoprognostic Classification of Peripheral Neuroblastic Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3719-3720.	1.6	1
140	Changes in ctDNA levels after MIBG therapy in patients with relapsed or refractory neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10012-10012.	1.6	1
141	A case of bilateral pachychoroid disease: polypoidal choroidal vasculopathy in one eye and peripheral exudative hemorrhagic chorioretinopathy in contralateral eye. <i>BMC Ophthalmology</i> , 2021, 21, 320.	1.4	1
142	Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors. , 2001, 92, 2699.		1
143	Neuroblastoma or not neuroblastoma. <i>Human Pathology</i> , 2014, 45, 662-663.	2.0	0
144	The Role of the Clinical Laboratory in the Diagnosis of Neuroblastoma. <i>journal of applied laboratory medicine, The</i> , 2020, 5, 254-256.	1.3	0

#	ARTICLE	IF	CITATIONS
145	A unique composite tumour of the adrenal gland in a paediatric patient, with adrenal cortical and neural crest cell-like components. <i>Pathology</i> , 2021, 53, 668-670.	0.6	0
146	Outcome analysis of non-high-risk neuroblastoma patients enrolled on Children's Oncology Group trials P9641 and A3961.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9533-9533.	1.6	0
147	Effect of insulin-like growth factor 2 gene expression on pleuropulmonary blastoma and embryonal rhabdomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9564-9564.	1.6	0
148	Genome-based outcome prediction in MYCN nonamplified high-risk neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9534-9534.	1.6	0
149	Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) to predict outcome in patients with stage 4 disease: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10015-10015.	1.6	0
150	Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10556-10556.	1.6	0
151	Abstract 1293: MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. , 2020, , .		0
152	Intraocular lens implantation and vitrectomy using 0.025% povidone-iodine in irrigation solution for bleb-related endophthalmitis. <i>International Journal of Ophthalmology</i> , 2020, 13, 1499-1502.	1.1	0
153	Composite Neuroblastoma Metastatic to a Lymph Node: The Novel Histopathologic Diagnosis of a Unique Multiclonal Neoplasm. <i>Annals of Clinical and Laboratory Science</i> , 2021, 51, 573-579.	0.2	0